Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental lung cancer combo trial ends early

NCT ID NCT04914897

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times

Summary

This phase 2 trial tested a new drug called THOR-707 (Pegenzileukin) combined with other cancer treatments, including pembrolizumab, in 106 people with advanced lung cancer or pleural mesothelioma. The goal was to see if the combination could shrink tumors. However, the study was terminated early, so the full results are not available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Investigational Site Number : 0320002

    CABA, Buenos Aires, 1430, Argentina

  • Investigational Site Number : 0360002

    Richmond, Victoria, 3121, Australia

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, 8420383, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, 7500921, Chile

  • Investigational Site Number : 1520003

    Temuco, 4800827, Chile

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, 7500713, Chile

  • Investigational Site Number : 1520005

    Santaigo, Reg Metropolitana de Santiago, 8241470, Chile

  • Investigational Site Number : 1580002

    Tainan, 704, Taiwan

  • Investigational Site Number : 1580003

    Taichung, 404, Taiwan

  • Investigational Site Number : 1580005

    Taipei, Taiwan

  • Investigational Site Number : 2500001

    Saint-Herblain, 44800, France

  • Investigational Site Number : 2500003

    Toulouse, 31059, France

  • Investigational Site Number : 2500005

    Paris, 75018, France

  • Investigational Site Number : 2500006

    Bordeaux, France

  • Investigational Site Number : 3800001

    Rozzano, Milano, 20089, Italy

  • Investigational Site Number : 3800002

    Orbassano, Torino, 10043, Italy

  • Investigational Site Number : 3800004

    Milan, 20133, Italy

  • Investigational Site Number : 3800005

    Aviano (PN), Friuli Venezia Giulia, 33081, Italy

  • Investigational Site Number : 3800006

    Bologna, 40138, Italy

  • Investigational Site Number : 3800008

    Padova, 35128, Italy

  • Investigational Site Number : 3920001

    Sapporo, Hokkaido, 003-0804, Japan

  • Investigational Site Number : 4100001

    Seoul, Seoul-teukbyeolsi, 06351, South Korea

  • Investigational Site Number : 4100002

    Seoul, Seoul-teukbyeolsi, 03080, South Korea

  • Investigational Site Number : 4100003

    Seoul, Seoul-teukbyeolsi, 05505, South Korea

  • Investigational Site Number : 6160001

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Investigational Site Number : 6160002

    Poznan, Greater Poland Voivodeship, 60-693, Poland

  • Investigational Site Number : 6160003

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

  • Investigational Site Number : 6160004

    Olsztyn, Warmian-Masurian Voivodeship, 10-357, Poland

  • Investigational Site Number : 7240001

    Madrid, 28041, Spain

  • Investigational Site Number : 7240002

    Madrid, 28034, Spain

  • Investigational Site Number : 7240003

    Girona, Girona [Gerona], 17007, Spain

  • Investigational Site Number : 7240004

    Madrid, Madrid, Comunidad de, 28046, Spain

  • Investigational Site Number : 7240006

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Thomas Jefferson University - North East Site Number : 8401009

    Philadelphia, Pennsylvania, 19114, United States

  • Thomas Jefferson University Hospital Site Number : 8400009

    Philadelphia, Pennsylvania, 19107, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

THOR-707 (Pegenzileukin) combined with pembrolizumab

What this could lead to

If successful, this combination could offer a new treatment option for people with certain types of lung cancer or mesothelioma.

What could go wrong

The trial was terminated early, so we don't have full results. It's unclear if the combination is effective or safe enough to continue.

Conditions

The condition(s) this trial relates to.

Mesothelioma, Malignant non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CANCER NON SMALL CELL LUNG CANCER PLEURAL MESOTHELIOMA